Drug intelligence / Profile preview

alpha-cypermethrin

Development stage
Unknown
Lead developer
FMC Corporation
Modality
Small Molecules
Administration
Topical
01

Overview

Alpha-cypermethrin is a highly active synthetic Type II pyrethroid insecticide consisting of the two most biologically active stereoisomers of cypermethrin (the (1R,cis)-alpha-S and (1S,cis)-alpha-R enantiomers). It acts as a potent modulator of voltage-gated sodium channels in insect neurons, delaying channel inactivation and causing prolonged sodium influx, which leads to repetitive nerve firing, hyperexcitation, paralysis, and death. Originally developed by Shell International Chemical Company in the 1980s and later acquired/marketed by BASF, FMC, and other agrochemical companies, alpha-cypermethrin is widely used in agriculture to control chewing and sucking pests, in public health for vector control (such as indoor residual spraying and insecticide-treated nets for malaria prevention), and in veterinary medicine to control ectoparasites.

Brand names
A-Cyper 100ECA-Cyper100ECA-Cyper-100ECAlfasectAlertAlpha C 6EDAlphamex 100 ECAlphamex100 ECAlphamex-100 ECAlphax 100Alphax100Alphax-100Bestox 100 ECBestox100 ECBestox-100 ECBestox 7.5 ULVBestox7.5 ULVBestox-7.5 ULVConcordContestCy-Kick ACFastacFastac 10 ECFastac10 ECFastac-10 ECFastac DryFastac DuoFedona 6 SCFedona6 SCFedona-6 SCFedona CSFendonaFendona 15 SCFendona15 SCFendona-15 SCFendona CSPT Cy-Kick ACPT FendonaRallis Alpha 10 ECRallis Cyper 10 ECRalothrin 10 ECRalothrin10 ECRalothrin-10 ECRalothrin 5 ECRalothrin5 ECRalothrin-5 ECRenegadeRoyal Sentry 2.0
Other names
alfamethrinalfoxylatealphacypermethrinalphamethrin
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on alpha-cypermethrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-cypermethrin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call